Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
July 8, 2021
-
BUSINESS Bristol Myers Kicks Off COVID-19 Inoculation Program, Eliminates Cost Burden on Employees
July 8, 2021
-
BUSINESS 26 Japan Drug Makers’ Annual Pay Averages 8.21 Million Yen, 5 Firms Top 10 Million Yen Mark
July 7, 2021
-
BUSINESS Astellas Revamping Sales Organization as Product Mix Shifts towards Specialty Area: CEO
July 6, 2021
-
BUSINESS Sagent Jettisons Camostat Mesilate for COVID-19 after PII Miss: Nichi-Iko
July 6, 2021
-
BUSINESS All Ranitidine Tablet Drugs to Be Discontinued in Japan over Carcinogen Woes
July 5, 2021
-
BUSINESS Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
-
BUSINESS 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
-
BUSINESS Ayumi to Leverage IT to Boost Sales and Marketing, Eyes More Licensing Deals
July 2, 2021
-
BUSINESS New BMS Japan Boots Up with Richer Cancer Assets as Celgene Merger Closes
July 1, 2021
-
BUSINESS 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
-
BUSINESS Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
-
BUSINESS Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
-
BUSINESS MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts
June 28, 2021
-
ACADEMIA Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
-
BUSINESS Japan Pharma Market Forecast to Decline through FY2025: IQVIA
June 25, 2021
-
ACADEMIA Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
June 25, 2021
-
REGULATORY Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
-
REGULATORY Japan to Stop Accepting Requests for Moderna Vaccines for Workplace Inoculations
June 24, 2021
-
BUSINESS MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
June 23, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…